{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-033874","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.017128+00:00","generated_at":"2026-05-31T13:51:33.183508+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"C4 Therapeutics Q2 net loss narrows to $17.7M; cash $295.7M; CFT1946 ESMO data Sept 14","bullets":["Revenue $12.0M vs $2.7M YoY, driven by $8M Biogen milestone.","Net loss $17.7M ($0.26 per share) vs $35.9M ($0.73) in Q2 2023.","Cash $295.7M; expects runway into 2027.","CFT1946 Phase 1 monotherapy data to be presented at ESMO Congress 2024 on Sept 14.","Cemsidomide Phase 1 data in MM and NHL on track for Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-033874","json":"https://secwatch.observer/filing/0001628280-24-033874.json","markdown":"https://secwatch.observer/filing/0001628280-24-033874.md","text":"https://secwatch.observer/filing/0001628280-24-033874.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828024033874/0001628280-24-033874-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828024033874/cccc-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:51:33.183508+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}